[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619322":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":33,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Aurélien GUFFROY, MD","CONTACT","33 3 69 5512 23","aurelien.guffroy@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France",{"type":22,"coordinates":23},"Point",[24,25],7.74553,48.58392,{"lat":25,"lon":24},[28,29,31],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":30,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":32,"role":30,"phone":7,"phoneExt":7,"email":7},"Jeannne MALLICK, MD",{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619322",false,"NCT07343115","Familial Systemic Scleroderma","SCLERO","Inclusion Criteria:\n\n* Adult subjects (≥ 18 years of age)\n* Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities\n* At least one first-degree relative with systemic scleroderma meeting the same criteria\n\nExclusion Criteria:\n\n\\- Subject who has expressed opposition to participating in the study","ALL","18 Years",{"count":44,"type":45},20,"ESTIMATED","OBSERVATIONAL","Studying familial forms of systemic scleroderma offers several advantages:\n\n1. To better understand the pathophysiology of a complex autoimmune disease based on \"extreme\" cases (familial forms);\n2. To identify potential molecular markers predictive of disease progression;\n3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.",[49],"Systemic Scleroderma",[49,38,51],"Autoimmune disease","2026-01-06",{"date":54,"type":55},"2026-01-15","ACTUAL",{"date":57,"type":55},"2025-09-02",{"date":59,"type":45},"2026-09-02",{"name":5,"class":6},1]